logo-loader
Genprex, Inc.

Genprex retains pharma branding agency to select a name for its lead drug

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

Varner says Addison Whitney is helping with the naming process of the drug, which could take a few months to a year.

Quick facts: Genprex, Inc.

Price: $0.88

Market: NASDAQ
Market Cap: $13.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

2 days ago

2 min read